Lawmakers tackle insulin prices, next steps on Alzheimer’s

Amid anger over the rising cost of insulin, the House Energy and Commerce Committee will hear from patients, diabetes advocacy organizations, and medical experts this morning. But absent from the hearing are the three big insulin makers — Eli Lilly, Sanofi, and Novo Nordisk — which have received the brunt of the criticism.

Elsewhere on Capitol Hill, the Senate Aging Committee is meeting this morning to discuss next steps and new directions on Alzheimer’s disease research. The hearing comes just two weeks after Biogen and its partner Eisai announced they were discontinuing two late-stage trials for their drug aducanumab because it did not appear to be working, dashing patient hopes for a long-awaited treatment for the disease.